PolyNovo Limited

ASX PNV.AX

PolyNovo Limited Free Cash Flow Yield on January 14, 2025: 0.06%

PolyNovo Limited Free Cash Flow Yield is 0.06% on January 14, 2025, a 108.17% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • PolyNovo Limited 52-week high Free Cash Flow Yield is 0.13% on October 13, 2024, which is 131.03% above the current Free Cash Flow Yield.
  • PolyNovo Limited 52-week low Free Cash Flow Yield is -0.72% on January 16, 2024, which is -1,337.93% below the current Free Cash Flow Yield.
  • PolyNovo Limited average Free Cash Flow Yield for the last 52 weeks is -0.19%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
ASX: PNV.AX

PolyNovo Limited

CEO Mr. Swami Raote BPHARM, M.B.A.
IPO Date Nov. 30, 1998
Location Australia
Headquarters 320 Lorimer Street
Employees 254
Sector Health Care
Industries
Description

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Similar companies

PME.AX

Pro Medicus Limited

USD 157.25

0.24%

MP1.AX

Megaport Limited

USD 4.12

1.00%

NAN.AX

Nanosonics Limited

USD 2.01

-0.68%

StockViz Staff

January 15, 2025

Any question? Send us an email